Alkem Laboratories share price

Balanced risk
  • 25%Low risk
  • 25%Moderate risk
  • 25%Balanced risk
  • 25%High risk
  • 25%Extreme risk
  • 4,804.60(-0.17%)
    June 18, 2025 15:52:58 PM IST
    • NSE
    • BSE
  • Vol : 121.04K (NSE + BSE)
    Last 20 day avg : 372.43 K

Alkem Laboratories is trading -0.17% lower at Rs 4,804.60 as compared to its last closing price. Alkem Laboratories has been trading in the price range of 4,823.10 & 4,776.00. Alkem Laboratories has given -14.57% in this year & -2.94% in the last 5 days. Alkem Laboratories has TTM P/E ratio 26.95 as compared to the sector P/E of 23.94.There are 17 analysts who have initiated coverage on Alkem Laboratories. There are 1 analysts who have given it a strong buy rating & 5 analysts have given it a buy rating. 4 analysts have given the stock a sell rating.The company posted a net profit of 305.86 Crores in its last quarter.Listed peers of Alkem Laboratories include Lupin (0.51%), Abbott India (-0.92%), Alkem Laboratories (-0.17%).The Mutual Fund holding in Alkem Laboratories was at 14.97% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Alkem Laboratories was at 9.40% in 31 Mar 2025. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Key Metrics

Updated on Jun 18, 2025, 10:36 PM UTC

  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.93
    Inline with the industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    4.80
    In line with historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    26.58
    Lower than historical values
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.82
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.12
    Higher than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
4,776.00
Highest
4,823.10
52 week range
Lowest
4,498.90
Highest
6,440.00
Alkem Laboratories Financials
Financials
Financials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
View all
  • Income
  • Balance Sheet
  • Cash Flow
Loading...
Units in the chart are in crores
Insights
  • Financial
  • Valuation
    • financial-insightsCompany is profitable
    • financial-insightsThe company's revenue grew in March quarter by 7.08% from Rs 3143.75 crore to Rs 2935.82 crore, year-on-year
    • financial-insightsThe company has grown its March quarter profit by 4.19% from Rs 293.56 crore to Rs 305.86 crore, year-on-year
    • financial-insightsThe debt to equity of the company is higher than the industry median
    • financial-insightsCompany can comfortably pay off its interest obligations with its earnings
Alkem Laboratories Technical Analysis
Pivot Level - classic
Info
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
  • R1
  • 5,323.48
  • R2
  • 5,551.27
  • R3
  • 5,835.73
Pivot5,039.02
  • S1
  • 4,811.23
  • S2
  • 4,526.77
  • S3
  • 4,298.98
Short Term
Info
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Info
Considers price movement over the last 6 months
Not Available
  • Very Bearish
  • Bearish
  • Neutral
  • Very Bullish
  • Bullish
Trends unavailable at the moment.
Alkem Laboratories Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Lupin
Bearish
1,953.450.5189,213.1828.055.340.4011.80
Abbott India
Bullish
31,510.00-0.9266,963.6147.5915.91.503.73
Alkem Laboratories
Bearish
4,804.60-0.1757,596.3926.884.860.924.83
Glaxosmithkline Pharmaceutical
Bullish
3,277.350.7755,765.4861.7229.231.250.13
Glenmark Pharmaceuticals
Bullish
1,659.100.3246,819.9435.825.370.157.90
Alkem Laboratories Shareholding
View All
Shareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
    No Data
    Shareholding pattern for Alkem Laboratories is currently unavailable
    Please check back later.
    Shareholding Insights
    • InsightsPromoter(s) holds a high stake in the company at 55.13%
    • InsightsPromoter(s) have decreased the stake in the company in last 12 months
    • InsightsFIIs are invested in this company
    • InsightsFIIs holding has decreased by 0.74 percentage points from previous quarter
    • InsightsMutual Funds holding has increased by 0.96 percentage points from previous quarter
    Mutual Fund Ownership
    View all
    Tata Nifty MidSmall Healthcare Index Fund Regular Growth
    NA
    • Amount Invested (Cr.) 6.66
    • % of AUM 4.88
    Motilal Oswal Nifty MidSmall Healthcare Index Fund Regular Growth
    NA
    • Amount Invested (Cr.) 1.18
    • % of AUM 4.86
    ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth
    NA
    • Amount Invested (Cr.) 227.10
    • % of AUM 4.12
    NJ ELSS Tax Saver Scheme Regular Growth
    NA
    • Amount Invested (Cr.) 10.63
    • % of AUM 3.92
    LIC MF Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 3.17
    • % of AUM 3.76
    Alkem Laboratories Corporate Actions
    View all
    • Board Meetings
    • AGM
    • Dividends
    • Bonus
    • Split
    • Rights
    Meeting DatePurpose
    2025-05-29Audited Results & Final Dividend
    2025-02-07Quarterly Results & Interim Dividend
    2024-11-13Quarterly Results
    2024-08-09Quarterly Results
    2024-05-29Audited Results & Final Dividend
    About the company Alkem Laboratories
    • IndustryBiotechnology & Drugs
    • ISININE540L01014
    • BSE Code539523
    • NSE CodeALKEM
    Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.
    • Management Info
    • Basudeo SinghExecutive Chairman of the Board
    • Vikas GuptaChief Executive Officer
    • Nitin AgrawalPresident - Finance, Chief Financial Officer
    • Manish NarangPresident - Legal, Chief Compliance Officer, Company Secretary
    • Sandeep SinghManaging Director, Executive Director
    • Madhurima SinghExecutive Director
    • Mritunjay SinghExecutive Director
    • Sarvesh SinghExecutive Director
    • Srinivas SinghExecutive Director
    Alkem Laboratories Share Price FAQs

    Alkem Laboratories is trading at 4804.60 as on Wed Jun 18 2025 10:22:58. This is -0.17% lower as compared to its previous closing price of 4812.65.

    The market capitalization of Alkem Laboratories is 57596.39 Cr as on Wed Jun 18 2025 10:22:58.

    The average broker rating on Alkem Laboratories is Hold. The breakup of analyst rating is given below -

    • 1 analysts have given a strong buy rating
    • 5 analysts have given a buy rating
    • 4 analysts have given a hold rating
    • 4 analysts have given a sell rating
    • 3 analysts have given a strong sell rating

    The 52 wk high for Alkem Laboratories is 6440.00 whereas the 52 wk low is 4498.90

    Alkem Laboratories can be analyzed on the following key metrics -

    • TTM P/E: 26.95
    • Sector P/E: 23.94
    • Dividend Yield: 0.93%
    • D/E ratio: 0.12

    Alkem Laboratories reported a net profit of 2165.48 Cr in 2025.

    The Mutual Fund Shareholding was 14.97% at the end of 31 Mar 2025.